e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
The immunology of allergic airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations
Claus Kroegel (Jena, Germany), Claus Kroegel, Martin Foerster, Kristin Lerche, Maryam Aalamian-Mattheis, Janett Happe, Anne Moeser, Stephanie Korn
Source:
International Congress 2015 – The immunology of allergic airway disease
Session:
The immunology of allergic airway disease
Session type:
Thematic Poster Session
Number:
2561
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Claus Kroegel (Jena, Germany), Claus Kroegel, Martin Foerster, Kristin Lerche, Maryam Aalamian-Mattheis, Janett Happe, Anne Moeser, Stephanie Korn. Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations. Eur Respir J 2015; 46: Suppl. 59, 2561
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma
Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding
Year: 2016
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Total and free IgE in evolution of severe asthma after omalizumab treatment
Source: International Congress 2016 – Asthma management
Year: 2016
A clinically observed variability in serum total IgE in patients being considered for omalizumab therapy
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Assessment of serum magnesium level in patients with bronchial asthma
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013
Evaluation of vitamin D in asthma: Its effect on inflammatory markers and clinical profile
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Usefulness of induced sputum eosinophil count to assess severity and treatment outcome in asthma patients
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Effect of tralokinumab on serum periostin and IgE levels in uncontrolled severe asthma
Source: International Congress 2015 – Advances in the future treatment of severe asthma
Year: 2015
Correlation between asthma control and serum levels of IL-33 in atopic asthma
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016
A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids
Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases
Year: 2013
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016
A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
Laser acupuncture effects on serum immunoglobulin E in A topic bronchial asthma patients
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement
Source: Annual Congress 2013 –Origins and diagnosis of asthma
Year: 2013
Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study
Source: International Congress 2015 – Asthma mechanisms and management
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept